Contrasting Hyperion DeFi (NASDAQ:HYPD) & PharmaTher (OTCMKTS:PHRRF)

Hyperion DeFi (NASDAQ:HYPD) and PharmaTher (OTCMKTS:PHRRF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk.

Earnings & Valuation

This table compares Hyperion DeFi and PharmaTher”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Hyperion DeFi	$810,000.00	65.67	-$45.31 million	($11.80)	-0.40
PharmaTher	N/A	N/A	N/A	N/A	N/A

PharmaTher has lower revenue, but higher earnings than Hyperion DeFi.

Profitability

This table compares Hyperion DeFi and PharmaTher’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Hyperion DeFi	N/A	-129.97%	-92.39%
PharmaTher	N/A	N/A	N/A

Insider & Institutional Ownership

25.8% of Hyperion DeFi shares are owned by institutional investors. 10.9% of Hyperion DeFi shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current recommendations for Hyperion DeFi and PharmaTher, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Hyperion DeFi	2	0	1	1	2.25
PharmaTher	0	0	0	0	0.00

Hyperion DeFi presently has a consensus target price of $5.88, indicating a potential upside of 25.80%. Given Hyperion DeFi’s stronger consensus rating and higher probable upside, analysts plainly believe Hyperion DeFi is more favorable than PharmaTher.

Summary

Hyperion DeFi beats PharmaTher on 7 of the 9 factors compared between the two stocks.

About Hyperion DeFi

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

About PharmaTher

PharmaTher Holdings Ltd., a specialty pharmaceutical company, develops and commercialize specialty pharmaceuticals exhibiting the adoption and permitting novel delivery methods to enhance patient outcomes. The company's product pipeline includes KETARX, a hydrochloride injection for the treatment of Parkinson's disease, Amyotrophic Lateral Sclerosis, complex regional pain and Rett syndrome, and anesthesia and procedural sedation, as well as Ischemia reperfusion injury. It also develops KETARX, a microneedle patch, for mental health, neurological, and pain disorders; and KETARX On-body pump for the maintenance of general anesthesia for diagnostic and surgical procedures. In addition, the company offers PHARMAPATCH, a microneedle patch technology solution, which includes hydrogel-forming and gelatin methacryloyl delivery system for the treatment of psychedelics and infectious diseases. Further, it has license agreement with BioRAE, Inc. for the development and commercialization of a novel biocompatible and biodegradable gelatin methacryloyl microneedle; and the University of Kansas to develop and commercialize the intellectual property of ketamine to treat ALS. The company also holds a patent and know-how license agreement with The Queen's University of Belfast to develop and commercialize hydrogel-forming microneedle patch delivery technology; and a license agreement with Gesval SA, as well as valuation and exclusive option agreement with Case Western Reserve University for development and commercialization for the intellectual property of ketamine for the treatment of Rett syndrome. PharmaTher Holdings Ltd. was incorporated in 2019 and is headquartered in Toronto, Canada.